What Lies Beneath: Current and Emerging Treatments for Prurigo Nodularis


Patients with prurigo nodularis (PN) can often go for years undiagnosed, misdiagnosed, and as a result, not properly managed. In this Care Team Forum®, we hear firsthand from Tiwana on how it was like living with PN, the impact it has had on her life, her experience seeking medical care, and how she integrates her therapeutic plan into her life. Joining her in discussion are Drs. Shawn Kwatra, Sarina Elmariah, and Sarah Chisolm who will discuss PN from a pathophysiological perspective, highlighting the role of type 2 inflammation, current and newly approved treatment options, as well as emerging therapies for PN.


Provided by RMEI Medical Education, LLC

Target Audience

Dermatology and primary care clinicians

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify elements of type 2 inflammation that play a role in prurigo nodularis (PN) pathogenesis that may be amenable to treatment
  • Examine the impact of current and emerging therapies on the management of PN



Shawn Kwatra, MD
Associate Professor, Dermatology and Oncology
Director, Johns Hopkins Itch Center
Johns Hopkins University School of Medicine
Baltimore, MD

Sarah S. Chisolm, MD
Assistant Professor and Director, Clinical Trials, Department of Dermatology
Emory University
Managing Director, ITCH-E (Itch Translational and Clinical Home at Emory)
Staff Physician, VISN 7, VA
Emory University Hospital
Atlanta, GA

Sarina B. Elmariah, MD, PhD, MPH
Associate Professor, Dermatology
Director, UCSF Center for Itch and Neurosensory Disorders
University of California, San Francisco
San Francisco, CA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.


Sarah S. Chisolm, MD, has relevant financial relationships with AbbVie, AstraZeneca, CSL Vifor, Galderma, Janssen Pharmaceuticals, Kimberly-Clark, Kiniksa Pharmaceuticals, Pfizer, Regeneron, Sanofi, Trevi Therapeutics, VYNE Therapeutics, Inc., formerly Menlo Therapeutics (Advisor); Amgen, Incyte Corporation, Pfizer (Researcher).

Sarina B. Elmariah, MD, PhD, MPH, has relevant financial relationships with BELLUS Health Inc., Galderma, New Frontier Bio, Inc., RAPT Therapeutics, Regeneron, Sanofi, Trevi Therapeutics (Advisor); Incyte Corporation, Regeneron, Sanofi (Speaker/Speaker’s Bureau).

Shawn Kwatra, MD, has relevant financial relationships with AbbVie, Aslan Pharmaceuticals, Arcutis Biotherapeutics, Inc., Castle Biosciences, Celldex Therapeutics, Inc., Galderma, Genzada Pharmaceuticals USA, Inc., Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi (Consultant); Galderma, Incyte Corporation, Pfizer, Sanofi (Grant/Research Support).

Patient participating in this activity has relevant financial relationships with Regeneron, Sanofi (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.


Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit


There is no fee to participate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.


Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.